Use of cathepsin K inhibition for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure

1. A method of treatment of pulmonary hypertension comprising administering an effective amount of a Cathepsin K inhibitor to a human or animal in need thereof, wherein the Cathepsin K inhibitor is a compound of formula (I) to (XIV) or (XV)

Com-

Stucture

pound

Name

(I)

(II)

(III)

(IV)

(V)

(VI)

(VII)

(VIII)

(IX)

MIV 701 (X), Ono 5334 (XI), RO 4383315 (XII), SAR-114137 (XIII), MIV 710 (XIV), or MIV 711 (XV).

2. The method of claim 1 , wherein the Cathepsin K inhibitor is a compound of formula (I)

3. A method of treatment of pulmonary hypertension comprising administering to a human or animal in need thereof an effective amount of a compound of formula (I)

or a salt thereof.

4. The method of claim 1 , wherein the Cathepsin K inhibitor is administered orally.

5. A method for treatment of pulmonary hypertension in humans and animals comprising administering to a human or animal a therapeutically effective amount of a pharmaceutical composition comprising at least one Cathepsin K inhibitor and an inert, non-toxic, pharmaceutically acceptable additive, wherein the Cathepsin K inhibitor is a compound of formula (I) to (XIV) or (XV)

Com-

Stucture

pound

Name

(I)

(II)

(III)

(IV)

(V)

(VI)

(VII)

(VIII)

(IX)

MIV 701 (X), Ono 5334 (XI), RO 4383315 (XII), SAR-114137 (XIII), MIV 710 (XIV), or MIV 711 (XV).

6. The method of claim 5 , wherein the Cathepsin K inhibitor is a compound of formula (I)